Primary biliary cirrhosis and overlap syndromes. Diagnosis and therapy;Primär biliäre leberzirrhose und overlap-syndrome: Diagnostik und therapie

Internist

Volumn 45, Issue 1, 2004, Pages 16-26

  Strassburg, C P ^a   Manns, M P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antimitochondrial antibodies; Autoimmune hepatitis; Cholestasis; Primary biliary cirrhosis; Ursodeoxycholic acid

Indexed keywords

ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; BILIRUBIN; BUDESONIDE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN A; GAMMA GLUTAMYLTRANSFERASE; HLA DR ANTIGEN; HLA DR8 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MITOCHONDRION ANTIBODY; PENICILLAMINE; PREDNISONE; STEROID; SULINDAC; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; BILIRUBIN BLOOD LEVEL; CHRONIC LIVER DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; ECHOGRAPHY; HUMAN; IMMUNOGENETICS; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; OVERLAP SYNDROME; PRIMARY BILIARY CIRRHOSIS; SIDE EFFECT; STEROID THERAPY; SYNDROME;

ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; AUTOIMMUNE DISEASES; HEPATITIS, AUTOIMMUNE; HLA-DR ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS, BILIARY; LIVER FUNCTION TESTS; MITOCHONDRIA, LIVER; PROGNOSIS; SYNDROME; URSODEOXYCHOLIC ACID;

EID: 0842300446     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-003-1127-x     Document Type: Article

References (60)

1. Angulo P, Smith C, Jorgensen RA (2000) Budesonide in the treatment of patients with primary biliary cirrhosis with suboptimal response to ursodeoxycholic acid. Hepatology 20:471-490
2. Bach N, Bodian C, Bodenheimer H et al. (2003) Methotrexate therapy for primary biliary cirrhosis. Am J Gastroenterol 98:187-193
3. Bandin O, Courvalin JC, Poupon R, Dubel L, Homberg JC, Johanet C (1996) Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Hepatology 23: 1020-1024
4. Berg PA, Klein R (1995) Mitochondrial antigen/antibody systems in primary biliary cirrhosis: revisited. Liver 15: 281-292
5. Bergasa NV (2003) Pruritus and fatigue in primary biliary cirrhosis. Clin Liver Dis 7: 879-900
6. Bluthner M, Schafer C, Schneider C, Bautz FA (1999) Identification of major linear epitopes on the sp100 nuclear PBC autoantigen by the gene-fragment phage-display technology. Autoimmunity 29: 33-42
7. Bodenheimer H, Schaffner F, Pezzullo J (1988) Evaluation of colchicine therapy in primary biliary cirrhosis. Gastroenterology 95: 124-129
8. Bodenheimer HC, Schaffner F, Sternlieb I et al. (1985) A prospective clinical trial of D-penicillamine in the treatment of primary biliary cirrhosis. Hepatology 5: 1139-1142
9. Brunner G, Klinge O, Christensen E et al. (1987) A chronic destructive non-suppurative cholangitis-like disease picture with antinuclear antibodies (immunocholangitis). Dtsch Med Wochenschr 112: 1454-1458
10. Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R (1998) Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 28: 296-301
11. Christensen E, Neuberger J, Crowe J et al. (1985) Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology 89: 1084-1091
12. Colombato LA, Alvarez F, Cote J, Huet PM (1994) Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis? Gastroenterology 107: 1839-1843
13. Courvalin JC, Worman HJ (1997) Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin Liver Dis 17: 79-90
14. Dickson ER, Fleming TR, Wiesner RH, Baldus WP, Fleming CR, Ludwig J, McCall JT (1985) Trial of penicillamine in advanced primary biliary cirrhosis. N Engl J Med 312: 1011-1015
15. Duclos-Vallee JC, Hadengue A, Ganne-Carrie N et al. (1995) Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Corticoresistance and effective treatment by cyclosporine A. Dig Dis Sci 40: 1069-1073
16. Floreani A (2002) Osteoporosis is not a specific complication of primary biliary cirrhosis (PBC). Gut 50: 898
17. Gershwin ME, Mackay IR (1991) Primary biliary cirrhosis: paradigm or paradox for autoimmunity. Gastroenterology 100: 822-833
18. Goulis J, Leandro G, Burroughs AK (1999) Randomised controlled trials of ursodeoxycholic acid therapy for primary biliary cirrhosis: a meta analysis. Lancet 354: 1053-1060
19. Heathcote EJ (1999) Evidence-based therapy of primary biliary cirrhosis. Eur J Gastroenterol Hepatol 11: 607-615
20. Heathcote J (2002) Variant syndromes of autoimmune hepatitis. Clin Liver Dis 6: 381-396
21. Heathcote J, Ross A, Sherlock S (1976) A prospective controlled trial of azathioprine in primary biliary cirrhosis. Gastroenterology 70: 656-660
22. Hendrickse MT, Rigney E, Giaffer MH et al. (1999) Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology 117: 400-407
23. Ikeda T, Tozuka S, Noguchi O (1996) Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: a prospective randomized study. J Hepatol 24: 88-94
24. James OF (1985) D-penicillamine for primary biliary cirrhosis. Gut 26: 109-113
25. Jones EA, Bergasa NV (1999) The pathogenesis and treatment of pruritus and fatigue in patients with PBC. Eur J Gastroenterol Hepatol 11: 623-631
26. Jones EA, Neuberger J, Bergasa NV (2002) Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions. QJM 95: 547-552
27. Kaplan MM, Alling DW, Zimmerman HJ et al. (1986) A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med 315:1448-1454
28. Krzeski P, Zych W, Kraszewska E, Milewski B, Butruk E, Habior A (1999) Is serum bilirubin concentration the only valid prognostic marker in primary biliary cirrhosis? Hepatology 30: 865-869
29. Leuschner M, Guldutuna S, You T, Hubner K, Bhatti S, Leuschner U (1996) Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. J Hepatol 25: 49-57
30. Leuschner M, Holtmeier J, Ackermann H et al. (2002) The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot study. Eur J Gastroenterol Hepatol 14: 1369-1376
31. Leuschner M, Maier KP, Schlichting J et al. (1999) Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 117: 918-925
32. Levy C, Lindor KD, Menon KV et al. (2003) Management of osteoporosis, fat-soluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis. Clin Liver Dis 7: 901-910
33. Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J (2001) Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 33: 22-27
34. Lombard M, Portmann B, Neuberger J et al. (1993) Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 104: 519-526
35. Manns MP, Strassburg CP (2001) Autoimmune hepatitis: clinical challenges. Gastroenterology 120: 1502-1517
36. Matloff DS, Alpert E, Resnick RH, Kaplan MM (1982) A prospective trial of D-penicillamine in primary biliary cirrhosis. N Engl J Med 306: 319-326
37. Mitchison HC, Palmer JM, Bassendine MF, Watson AJ, Record CO, James OF (1992) A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol 15: 336-344
38. Neuberger J (2000) Recurrent primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 14: 669-680
39. Neuberger J, Christensen E, Portmann B et al. (1985) Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis. Gut 26: 114-119
40. Pares A, Guanabens N, Alvarez L et al.(2001) Collagen type lalpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology 33: 554-560
41. Paumgartner G, Beuers U (2002) Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 36: 525-531
42. Poupon RE, Bonnand AM, Chretien Y, Poupon R (1999) Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology 29: 1668-1671
43. Poupon RE, Huet PM, Poupon R, Bonnand AM, Nhieu JT, Zafrani ES (1996) A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group. Hepatology 24:1098-1103
44. Poupon RE, Lindor KD, Cauch-Dudek K (1997) Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 113: 884-890
45. Poupon RE, Lindor KD, Pares A, Chazouilleres O, Poupon R, Heathcote EJ (2003) Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 39: 12-16
46. Raedsch R, Stiehl A, Walker S, Scherrmann JM, Kommerell B (1992) Combined ursodeoxycholic acid plus colchicine - treatment of primary biliary cirrhosis: results of a placebo-controlled double-blind study. Z Gastroenterol 30 (Suppl): 55-57
47. Serfaty L, De Leusse A, Rosmorduc O et al. (2003) Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology 38: 203-209
48. Shapiro JM, Smith H, Schaffner F (1979) Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 20: 137-140
49. Strassburg CP, Alex B, Zindy F et al. (1996) Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic autoimmune diseases. J Hepatol 25: 859-866
50. Strassburg CP, Jaeckel E, Manns MP (1999) Anti-mitochondrial antibodies and other immunological tests in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 11: 595-601
51. Strassburg CP, Manns MP (1996) Primär biliäre Zirrhose und primär sklerosierende Cholangitis. Intern Praxis 36: 57-74
52. Strassburg CR, Manns MP (2000) Autoimmune tests in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 14: 585-99
53. Strassburg CR Obermayer-Straub P, Manns MP (2000) Autoimmunity in liver diseases. Clin Rev Allergy Immunol 127-139
54. Taal BG, Schalm SW, Ten Kate FW, Van Berge Henegouwen GP, Brandt KH (1983) Low therapeutic value of D-penicillamine in a short-term prospective trial in primary biliary cirrhosis. Liver 3: 345-352
55. Van Steenbergen W, Sciot R, Van Eyken P, Desmet V, Fevery J (1996) Combined treatment with methotrexate and ursodeoxycholic acid in non-cirrhotic primary biliary cirrhosis. Acta Clin Belg 51: 8-18
56. Vogel A, Strassburg CP, Manns MP (2002) Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 35: 126-131
57. Vogel A, Wedemeyer H, Manns MP, Strassburg CP (2002) Autoimmune hepatitis and overlap syndromes. J Gastroenterol Hepatol 17 (Suppl): 5389-5398
58. Warnes TW, Smith A, Lee FI, Haboubi NY, Johnson PJ, Hunt L (1987) A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report. J Hepatol 5: 1-7
59. Wiesner RH, Ludwig J, Lindor KD, Jorgensen RA, Baldus WP, Homburger HA, Dickson ER (1990) A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med 322: 1419-1424
60. Wolfhagen FHJ, van Hoogstraaten HJF, van Buuren H.R. (1998) Triple therapy with ursodeoxycholic acid, prednisone, and azathioprine in primary biliary cirrhosis: a 1 year randomized, placebo controlled study. J Hepatol 29: 736-742